Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-07

AUTHORS

Roberto R. Giraldez, Stephen D. Wiviott, Jose C. Nicolau, Satishkumar Mohanavelu, David A. Morrow, Elliott M. Antman, Robert P. Giugliano

ABSTRACT

BACKGROUND: Enoxaparin was superior to unfractionated heparin (UFH), regardless of fibrinolytic agent in ST-elevation myocardial infarction (STEMI) patients receiving fibrinolytic therapy in ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction 25) trial. OBJECTIVE: This post hoc analysis compared outcomes with streptokinase plus enoxaparin to the standard regimen of fibrin-specific lytic (FSL) plus UFH and to the newer combination of FSL plus enoxaparin. METHODS: In ExTRACT-TIMI 25, STEMI patients received either streptokinase or a FSL (alteplase, reteplase or tenecteplase) at the physician's discretion and were randomized to enoxaparin or UFH, stratified by fibrinolytic type. Thirty-day outcomes were adjusted for baseline characteristics, region, in-hospital percutaneous coronary intervention (PCI) and a propensity score for the choice of lytic. RESULTS: The primary trial endpoint of 30-day death/myocardial infarction (MI) occurred in fewer patients in the streptokinase-enoxaparin cohort (n = 2083) compared with FSL-UFH (n = 8141) [10.2% vs 12.0%, adjusted odds ratio [OR(adj)] 0.76; 95% CI 0.62, 0.93; p = 0.008]. Major bleeding was significantly increased with streptokinase-enoxaparin compared with FSL-UFH (OR(adj) 2.74; 95% CI 1.81; 4.14; p < 0.001) but intracranial haemorrhage (ICH) was similar (OR(adj) 0.90; 95% CI 0.40, 2.01; p = 0.79). Net clinical outcomes, defined as either death/MI/major bleeding or as death/MI/ICH tended to favour streptokinase-enoxaparin compared with FSL-UFH (OR(adj) 0.88; 95% CI 0.73, 1.06; p = 0.17; and OR(adj) 0.77; 95% CI 0.63, 0.93; p = 0.008, respectively). Patients receiving FSL-enoxaparin (n = 8142) and streptokinase-enoxaparin therapies experienced similar adjusted rates of the primary endpoint (OR(adj) 1.08; 95% CI 0.87, 1.32; p = 0.49) and net clinical outcomes. CONCLUSIONS: Our results suggest that fibrinolytic therapy with the combination of streptokinase and the potent anticoagulant agent enoxaparin resulted in similar adjusted outcomes compared with more costly regimens utilizing a FSL. More... »

PAGES

1433-1443

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00003495-200969110-00003

DOI

http://dx.doi.org/10.2165/00003495-200969110-00003

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048836396

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19634922


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angioplasty, Balloon, Coronary", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Endpoint Determination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enoxaparin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fibrin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fibrinolytic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemorrhage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myocardial Infarction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Plasminogen Activators", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Streptokinase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tenecteplase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thrombolytic Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Plasminogen Activator", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giraldez", 
        "givenName": "Roberto R.", 
        "id": "sg:person.01300561764.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300561764.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wiviott", 
        "givenName": "Stephen D.", 
        "id": "sg:person.0642207645.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642207645.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Sao Paulo", 
          "id": "https://www.grid.ac/institutes/grid.11899.38", 
          "name": [
            "Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nicolau", 
        "givenName": "Jose C.", 
        "id": "sg:person.0607417223.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607417223.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mohanavelu", 
        "givenName": "Satishkumar", 
        "id": "sg:person.0777060255.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777060255.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morrow", 
        "givenName": "David A.", 
        "id": "sg:person.01002167617.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002167617.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Antman", 
        "givenName": "Elliott M.", 
        "id": "sg:person.015737165557.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015737165557.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giugliano", 
        "givenName": "Robert P.", 
        "id": "sg:person.0702207604.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702207604.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/jama.295.13.joc60038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002293863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199505253322106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007376285"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ahj.2004.08.038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009758285"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(99)07403-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009897504"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.293.4.427", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011815297"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.101.4_supplement.91s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012632789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200018010-00009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013494674", 
          "https://doi.org/10.2165/00019053-200018010-00009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200018010-00009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013494674", 
          "https://doi.org/10.2165/00019053-200018010-00009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0735-1097(02)02901-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013744591"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0735-1097(02)02901-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013744591"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199311253292204", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019874241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.102.17.2031", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020744727"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060898", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020761305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(01)06887-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022289272"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.aje.a010011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022666639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(95)92224-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026020371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(95)92224-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026020371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.97.17.1702", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031073278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.292.1.45", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034517372"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199011223232101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039290762"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199710163371603", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039566978"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehm179", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045265604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(01)06961-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045918353"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.293.21.2595-c", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048560677"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199309023291001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053195270"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(03)12712-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053680162"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-07", 
    "datePublishedReg": "2009-07-01", 
    "description": "BACKGROUND: Enoxaparin was superior to unfractionated heparin (UFH), regardless of fibrinolytic agent in ST-elevation myocardial infarction (STEMI) patients receiving fibrinolytic therapy in ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction 25) trial.\nOBJECTIVE: This post hoc analysis compared outcomes with streptokinase plus enoxaparin to the standard regimen of fibrin-specific lytic (FSL) plus UFH and to the newer combination of FSL plus enoxaparin.\nMETHODS: In ExTRACT-TIMI 25, STEMI patients received either streptokinase or a FSL (alteplase, reteplase or tenecteplase) at the physician's discretion and were randomized to enoxaparin or UFH, stratified by fibrinolytic type. Thirty-day outcomes were adjusted for baseline characteristics, region, in-hospital percutaneous coronary intervention (PCI) and a propensity score for the choice of lytic.\nRESULTS: The primary trial endpoint of 30-day death/myocardial infarction (MI) occurred in fewer patients in the streptokinase-enoxaparin cohort (n = 2083) compared with FSL-UFH (n = 8141) [10.2% vs 12.0%, adjusted odds ratio [OR(adj)] 0.76; 95% CI 0.62, 0.93; p = 0.008]. Major bleeding was significantly increased with streptokinase-enoxaparin compared with FSL-UFH (OR(adj) 2.74; 95% CI 1.81; 4.14; p < 0.001) but intracranial haemorrhage (ICH) was similar (OR(adj) 0.90; 95% CI 0.40, 2.01; p = 0.79). Net clinical outcomes, defined as either death/MI/major bleeding or as death/MI/ICH tended to favour streptokinase-enoxaparin compared with FSL-UFH (OR(adj) 0.88; 95% CI 0.73, 1.06; p = 0.17; and OR(adj) 0.77; 95% CI 0.63, 0.93; p = 0.008, respectively). Patients receiving FSL-enoxaparin (n = 8142) and streptokinase-enoxaparin therapies experienced similar adjusted rates of the primary endpoint (OR(adj) 1.08; 95% CI 0.87, 1.32; p = 0.49) and net clinical outcomes.\nCONCLUSIONS: Our results suggest that fibrinolytic therapy with the combination of streptokinase and the potent anticoagulant agent enoxaparin resulted in similar adjusted outcomes compared with more costly regimens utilizing a FSL.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00003495-200969110-00003", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1084788", 
        "issn": [
          "0012-6667", 
          "1179-1950"
        ], 
        "name": "Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "69"
      }
    ], 
    "name": "Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens", 
    "pagination": "1433-1443", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e8a5bd30d73bf8524126a1ff7b18658f7c23a11ce04ddb7c4b667b6e20b2b452"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19634922"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7600076"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00003495-200969110-00003"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048836396"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00003495-200969110-00003", 
      "https://app.dimensions.ai/details/publication/pub.1048836396"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000345_0000000345/records_64094_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00003495-200969110-00003"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003495-200969110-00003'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003495-200969110-00003'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003495-200969110-00003'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003495-200969110-00003'


 

This table displays all metadata directly associated to this object as RDF triples.

289 TRIPLES      21 PREDICATES      76 URIs      45 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00003495-200969110-00003 schema:about N0288afa2710f4c1ea6f0a89ea0e893ed
2 N0813e4af64fe49b49cea25aa40bfed29
3 N0a15fec8a48049b2962ad59b2e4711a5
4 N1aa58d631ca246aca5ce731b9d1d9a21
5 N2790bb3feb1d4f1a953e20b169a41d29
6 N422cb073773c4a2883ae457d474d07a5
7 N4b03c4cacce54d55985164b7177d57c1
8 N6a05138cff6a4717a758ec461bfb14eb
9 N754ee3f5125d4a92ac27db5b621469c9
10 N798c65f2551e484a8a11a346e890c806
11 N7e7235139f3c4d2e9da3a6819c8a5a73
12 N7fa59ccf923043c0927538c6360dba3b
13 N90192159d26f4ce5a01ab4516efdfbf6
14 N96ecf4e472d14d1dabb966859dd409f4
15 N9ab9f581b6b54f478ea2b8431d70e8a9
16 Na06b904b7fef4b059ffe93a9edeb3fd9
17 Na46ce0540c0746ca812d4a025ca79a17
18 Nbbf840ee7a64461fa2a2e8d3af45b7be
19 Nc317edb330564899b8e78f5f1c893c29
20 Nc4198f8122f94734bd988672a6bbeff4
21 Nd53501f0b2254e91bc4644ad9f1afdbb
22 Ndb57282b842649cfa00c723ece56b440
23 Ne23b5f09d68543acbaa9cfdd2979ed90
24 Nf51812bcec72448a8151a82dac4d57d2
25 anzsrc-for:11
26 anzsrc-for:1103
27 schema:author N6d8fd3baf8434e33908b0e6ba6005c2c
28 schema:citation sg:pub.10.2165/00019053-200018010-00009
29 https://doi.org/10.1001/jama.292.1.45
30 https://doi.org/10.1001/jama.293.21.2595-c
31 https://doi.org/10.1001/jama.293.4.427
32 https://doi.org/10.1001/jama.295.13.joc60038
33 https://doi.org/10.1016/j.ahj.2004.08.038
34 https://doi.org/10.1016/s0140-6736(01)06887-8
35 https://doi.org/10.1016/s0140-6736(01)06961-6
36 https://doi.org/10.1016/s0140-6736(03)12712-2
37 https://doi.org/10.1016/s0140-6736(95)92224-5
38 https://doi.org/10.1016/s0140-6736(99)07403-6
39 https://doi.org/10.1016/s0735-1097(02)02901-7
40 https://doi.org/10.1056/nejm199011223232101
41 https://doi.org/10.1056/nejm199309023291001
42 https://doi.org/10.1056/nejm199311253292204
43 https://doi.org/10.1056/nejm199505253322106
44 https://doi.org/10.1056/nejm199710163371603
45 https://doi.org/10.1056/nejmoa060898
46 https://doi.org/10.1093/eurheartj/ehm179
47 https://doi.org/10.1093/oxfordjournals.aje.a010011
48 https://doi.org/10.1161/01.cir.102.17.2031
49 https://doi.org/10.1161/01.cir.97.17.1702
50 https://doi.org/10.1378/chest.101.4_supplement.91s
51 schema:datePublished 2009-07
52 schema:datePublishedReg 2009-07-01
53 schema:description BACKGROUND: Enoxaparin was superior to unfractionated heparin (UFH), regardless of fibrinolytic agent in ST-elevation myocardial infarction (STEMI) patients receiving fibrinolytic therapy in ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction 25) trial. OBJECTIVE: This post hoc analysis compared outcomes with streptokinase plus enoxaparin to the standard regimen of fibrin-specific lytic (FSL) plus UFH and to the newer combination of FSL plus enoxaparin. METHODS: In ExTRACT-TIMI 25, STEMI patients received either streptokinase or a FSL (alteplase, reteplase or tenecteplase) at the physician's discretion and were randomized to enoxaparin or UFH, stratified by fibrinolytic type. Thirty-day outcomes were adjusted for baseline characteristics, region, in-hospital percutaneous coronary intervention (PCI) and a propensity score for the choice of lytic. RESULTS: The primary trial endpoint of 30-day death/myocardial infarction (MI) occurred in fewer patients in the streptokinase-enoxaparin cohort (n = 2083) compared with FSL-UFH (n = 8141) [10.2% vs 12.0%, adjusted odds ratio [OR(adj)] 0.76; 95% CI 0.62, 0.93; p = 0.008]. Major bleeding was significantly increased with streptokinase-enoxaparin compared with FSL-UFH (OR(adj) 2.74; 95% CI 1.81; 4.14; p < 0.001) but intracranial haemorrhage (ICH) was similar (OR(adj) 0.90; 95% CI 0.40, 2.01; p = 0.79). Net clinical outcomes, defined as either death/MI/major bleeding or as death/MI/ICH tended to favour streptokinase-enoxaparin compared with FSL-UFH (OR(adj) 0.88; 95% CI 0.73, 1.06; p = 0.17; and OR(adj) 0.77; 95% CI 0.63, 0.93; p = 0.008, respectively). Patients receiving FSL-enoxaparin (n = 8142) and streptokinase-enoxaparin therapies experienced similar adjusted rates of the primary endpoint (OR(adj) 1.08; 95% CI 0.87, 1.32; p = 0.49) and net clinical outcomes. CONCLUSIONS: Our results suggest that fibrinolytic therapy with the combination of streptokinase and the potent anticoagulant agent enoxaparin resulted in similar adjusted outcomes compared with more costly regimens utilizing a FSL.
54 schema:genre research_article
55 schema:inLanguage en
56 schema:isAccessibleForFree false
57 schema:isPartOf N1dd0d24ddda04814b62a6ba743440f40
58 N598fd046c3eb48289a88a4ddc2e7726f
59 sg:journal.1084788
60 schema:name Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens
61 schema:pagination 1433-1443
62 schema:productId N0425cb047721406c83b19d4ab6b4ef4c
63 N78ea918936a14a218215d072e82dcdfb
64 Nba8f2bc638094f868cc8482248ab8356
65 Nd65b8b1b1ba44f8f906eec8995aa8ec3
66 Ne75bf15134444f3da299e3a1cedefb9e
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048836396
68 https://doi.org/10.2165/00003495-200969110-00003
69 schema:sdDatePublished 2019-04-11T09:24
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher N853578be653e478a833fc369bf472c71
72 schema:url http://link.springer.com/10.2165/00003495-200969110-00003
73 sgo:license sg:explorer/license/
74 sgo:sdDataset articles
75 rdf:type schema:ScholarlyArticle
76 N0288afa2710f4c1ea6f0a89ea0e893ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Drug Therapy, Combination
78 rdf:type schema:DefinedTerm
79 N0425cb047721406c83b19d4ab6b4ef4c schema:name pubmed_id
80 schema:value 19634922
81 rdf:type schema:PropertyValue
82 N0813e4af64fe49b49cea25aa40bfed29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Time Factors
84 rdf:type schema:DefinedTerm
85 N0a15fec8a48049b2962ad59b2e4711a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Humans
87 rdf:type schema:DefinedTerm
88 N117a0b5a65b24aed8230da4f6dbf14a7 rdf:first sg:person.0702207604.00
89 rdf:rest rdf:nil
90 N1aa58d631ca246aca5ce731b9d1d9a21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Tissue Plasminogen Activator
92 rdf:type schema:DefinedTerm
93 N1cd866679d374d3a9890dcb5130c7d63 schema:name TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA
94 rdf:type schema:Organization
95 N1dd0d24ddda04814b62a6ba743440f40 schema:volumeNumber 69
96 rdf:type schema:PublicationVolume
97 N2790bb3feb1d4f1a953e20b169a41d29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Fibrin
99 rdf:type schema:DefinedTerm
100 N2e381596fad44aef902cc1a09b166410 rdf:first sg:person.0777060255.77
101 rdf:rest N9cbf0fbf730d44e79c18da085494cce3
102 N422cb073773c4a2883ae457d474d07a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Young Adult
104 rdf:type schema:DefinedTerm
105 N4a469735e2c34bd2843f5aa59695849c schema:name TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA
106 rdf:type schema:Organization
107 N4b03c4cacce54d55985164b7177d57c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Myocardial Infarction
109 rdf:type schema:DefinedTerm
110 N598fd046c3eb48289a88a4ddc2e7726f schema:issueNumber 11
111 rdf:type schema:PublicationIssue
112 N5ce14e0ea3f0474aadaadfbdb5976d14 rdf:first sg:person.0642207645.24
113 rdf:rest Nc004ff0891b643bc9172a09e1a39e9e2
114 N6a05138cff6a4717a758ec461bfb14eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Male
116 rdf:type schema:DefinedTerm
117 N6d8fd3baf8434e33908b0e6ba6005c2c rdf:first sg:person.01300561764.28
118 rdf:rest N5ce14e0ea3f0474aadaadfbdb5976d14
119 N754ee3f5125d4a92ac27db5b621469c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Treatment Outcome
121 rdf:type schema:DefinedTerm
122 N78ea918936a14a218215d072e82dcdfb schema:name readcube_id
123 schema:value e8a5bd30d73bf8524126a1ff7b18658f7c23a11ce04ddb7c4b667b6e20b2b452
124 rdf:type schema:PropertyValue
125 N798c65f2551e484a8a11a346e890c806 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Cohort Studies
127 rdf:type schema:DefinedTerm
128 N7e7235139f3c4d2e9da3a6819c8a5a73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Streptokinase
130 rdf:type schema:DefinedTerm
131 N7fa59ccf923043c0927538c6360dba3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Recombinant Proteins
133 rdf:type schema:DefinedTerm
134 N853578be653e478a833fc369bf472c71 schema:name Springer Nature - SN SciGraph project
135 rdf:type schema:Organization
136 N90192159d26f4ce5a01ab4516efdfbf6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Female
138 rdf:type schema:DefinedTerm
139 N96ecf4e472d14d1dabb966859dd409f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Hemorrhage
141 rdf:type schema:DefinedTerm
142 N9ab9f581b6b54f478ea2b8431d70e8a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Adult
144 rdf:type schema:DefinedTerm
145 N9cbf0fbf730d44e79c18da085494cce3 rdf:first sg:person.01002167617.85
146 rdf:rest Na6c9d89db0ab48ffa362b19d9e717a7a
147 N9dadfac7b87c431db5f0f738483ef2b9 schema:name TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA
148 rdf:type schema:Organization
149 Na06b904b7fef4b059ffe93a9edeb3fd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Angioplasty, Balloon, Coronary
151 rdf:type schema:DefinedTerm
152 Na46ce0540c0746ca812d4a025ca79a17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Tenecteplase
154 rdf:type schema:DefinedTerm
155 Na6c9d89db0ab48ffa362b19d9e717a7a rdf:first sg:person.015737165557.39
156 rdf:rest N117a0b5a65b24aed8230da4f6dbf14a7
157 Nb0019c54098046f4bb90c8158f848b30 schema:name TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA
158 rdf:type schema:Organization
159 Nba8f2bc638094f868cc8482248ab8356 schema:name dimensions_id
160 schema:value pub.1048836396
161 rdf:type schema:PropertyValue
162 Nbbf840ee7a64461fa2a2e8d3af45b7be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Plasminogen Activators
164 rdf:type schema:DefinedTerm
165 Nc004ff0891b643bc9172a09e1a39e9e2 rdf:first sg:person.0607417223.32
166 rdf:rest N2e381596fad44aef902cc1a09b166410
167 Nc317edb330564899b8e78f5f1c893c29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Enoxaparin
169 rdf:type schema:DefinedTerm
170 Nc4198f8122f94734bd988672a6bbeff4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Middle Aged
172 rdf:type schema:DefinedTerm
173 Nd53501f0b2254e91bc4644ad9f1afdbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Fibrinolytic Agents
175 rdf:type schema:DefinedTerm
176 Nd65b8b1b1ba44f8f906eec8995aa8ec3 schema:name doi
177 schema:value 10.2165/00003495-200969110-00003
178 rdf:type schema:PropertyValue
179 Ndb57282b842649cfa00c723ece56b440 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Aged
181 rdf:type schema:DefinedTerm
182 Ne23b5f09d68543acbaa9cfdd2979ed90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Thrombolytic Therapy
184 rdf:type schema:DefinedTerm
185 Ne47596c2a59147c9ba75d7236bd1cc15 schema:name TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA
186 rdf:type schema:Organization
187 Ne75bf15134444f3da299e3a1cedefb9e schema:name nlm_unique_id
188 schema:value 7600076
189 rdf:type schema:PropertyValue
190 Nec4c1951d92948ad862bddd0fca7dce4 schema:name TIMI Study Group,Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor Offices, 02115, Boston, Massachusetts, USA
191 rdf:type schema:Organization
192 Nf51812bcec72448a8151a82dac4d57d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Endpoint Determination
194 rdf:type schema:DefinedTerm
195 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
196 schema:name Medical and Health Sciences
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
199 schema:name Clinical Sciences
200 rdf:type schema:DefinedTerm
201 sg:journal.1084788 schema:issn 0012-6667
202 1179-1950
203 schema:name Drugs
204 rdf:type schema:Periodical
205 sg:person.01002167617.85 schema:affiliation Nec4c1951d92948ad862bddd0fca7dce4
206 schema:familyName Morrow
207 schema:givenName David A.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002167617.85
209 rdf:type schema:Person
210 sg:person.01300561764.28 schema:affiliation Nb0019c54098046f4bb90c8158f848b30
211 schema:familyName Giraldez
212 schema:givenName Roberto R.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300561764.28
214 rdf:type schema:Person
215 sg:person.015737165557.39 schema:affiliation N4a469735e2c34bd2843f5aa59695849c
216 schema:familyName Antman
217 schema:givenName Elliott M.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015737165557.39
219 rdf:type schema:Person
220 sg:person.0607417223.32 schema:affiliation https://www.grid.ac/institutes/grid.11899.38
221 schema:familyName Nicolau
222 schema:givenName Jose C.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607417223.32
224 rdf:type schema:Person
225 sg:person.0642207645.24 schema:affiliation Ne47596c2a59147c9ba75d7236bd1cc15
226 schema:familyName Wiviott
227 schema:givenName Stephen D.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642207645.24
229 rdf:type schema:Person
230 sg:person.0702207604.00 schema:affiliation N1cd866679d374d3a9890dcb5130c7d63
231 schema:familyName Giugliano
232 schema:givenName Robert P.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702207604.00
234 rdf:type schema:Person
235 sg:person.0777060255.77 schema:affiliation N9dadfac7b87c431db5f0f738483ef2b9
236 schema:familyName Mohanavelu
237 schema:givenName Satishkumar
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777060255.77
239 rdf:type schema:Person
240 sg:pub.10.2165/00019053-200018010-00009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013494674
241 https://doi.org/10.2165/00019053-200018010-00009
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1001/jama.292.1.45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034517372
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1001/jama.293.21.2595-c schema:sameAs https://app.dimensions.ai/details/publication/pub.1048560677
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1001/jama.293.4.427 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011815297
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1001/jama.295.13.joc60038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002293863
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1016/j.ahj.2004.08.038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009758285
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1016/s0140-6736(01)06887-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022289272
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1016/s0140-6736(01)06961-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045918353
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1016/s0140-6736(03)12712-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053680162
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1016/s0140-6736(95)92224-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026020371
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1016/s0140-6736(99)07403-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009897504
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1016/s0735-1097(02)02901-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013744591
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1056/nejm199011223232101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039290762
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1056/nejm199309023291001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053195270
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1056/nejm199311253292204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019874241
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1056/nejm199505253322106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007376285
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1056/nejm199710163371603 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039566978
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1056/nejmoa060898 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020761305
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1093/eurheartj/ehm179 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045265604
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1093/oxfordjournals.aje.a010011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022666639
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1161/01.cir.102.17.2031 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020744727
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1161/01.cir.97.17.1702 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031073278
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1378/chest.101.4_supplement.91s schema:sameAs https://app.dimensions.ai/details/publication/pub.1012632789
286 rdf:type schema:CreativeWork
287 https://www.grid.ac/institutes/grid.11899.38 schema:alternateName University of Sao Paulo
288 schema:name Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil
289 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...